Applied Evidence

To avoid Hep B reactivation, screen before immunosuppression

Author and Disclosure Information

 

References

In screening, be sure the appropriate anti-HBc testing is covered. Common usage of the term anti-HBc may refer to immunoglobulin G (IgG) or immunoglobulin M (IgM)or total core antibody, containing both IgG and IgM. But in this context, accurate screening requires either total core antibody or anti-HBc IgG. Anti-IgM alone is inadequate. Many commercial laboratories offer acute hepatitis panels or hepatitis profiles (TABLE 324,25), and it is important to confirm that such order sets contain the tests necessary to allow for risk stratification.

Hepatitis panels and additional tests to request from common commercial laboratories

Testing for hepatitis B surface antibody (anti-HBs) is not useful in screening. Although it was hypothesized that the presence of this antibody lowered risk, recent studies have proven no change in risk based on this value.21

How to assess HBVr risk

Assessing risk for HBVr takes into account both the patient’s serology and intended treatment. Reddy et al delineated patient groups into high, moderate, and low risk (TABLES 4 and 5).21 The high-risk group was defined by anticipated incidence of HBVr in > 10% of cases; the moderate-risk group had an anticipated incidence of 1% to 10%; and the low-risk group had an anticipated incidence of <1%.21 Evidence was strongest in the high-risk group.

Risk of HBVr based on patient HBV serology and immunosuppressive agent

Patients with CHB (HBsAg positive and anti-HBc positive) are considered high risk for reactivation with a wide variety of immunosuppressive therapies. Such patients are 5 to 8 times more likely to develop HBVr than patients with an HBsAg-negative status signifying a resolved infection.16

Classification of corticosteroid dosages for risk stratification

Immunosuppressive agents and associated risks. The AGA guidelines consider treatment with B-cell-depleting agents, such as rituximab and ofatumumab, to be high risk, regardless of a patient’s surface antigen status. Additionally, for patients who are HBsAg positive, high-risk treatments include anthracycline derivatives, such as doxorubicin and epirubicin, or high- or moderate-dose steroids. These treatments are considered moderate risk when used in patients who have resolved HBV infection (HBsAg negative/anti-HBc positive). Moderate-risk modalities also include tumor necrosis factor inhibitors and tyrosine kinase inhibitors, regardless of surface antigen status; and low-dose steroids or cytokine or integrin inhibitors in HbsAg-positive individuals.21

Continue to: Other immunosuppression modalities...

Pages

Recommended Reading

Delaying antibiotics in elderly with UTI linked to higher sepsis, death rates
MDedge Family Medicine
Flu season shows signs of peaking
MDedge Family Medicine
Measles cases jumped 30% last week
MDedge Family Medicine
Don’t overlook this step in combatting the rise in STIs
MDedge Family Medicine
Take stronger steps to prevent staph infections and sepsis
MDedge Family Medicine
Infective endocarditis isn’t what it used to be
MDedge Family Medicine
Poor COPD management might increase MI risk in HIV
MDedge Family Medicine
One-time, universal hepatitis C testing cost effective, researchers say
MDedge Family Medicine
Hepatitis vaccination update
MDedge Family Medicine
Flu activity down for a second straight week
MDedge Family Medicine